Artiva Biotherapeutics to Join Global Healthcare Conference
SAN DIEGO — Artiva Biotherapeutics, Inc. (NASDAQ: ARTV), a clinical-stage biotechnology company, is preparing to take part in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference. The conversation, scheduled for an upcoming date, will focus on Artiva’s approach to creating safe, effective cell therapies for serious conditions where current treatments fall short. It’s a chance to hear directly from leadership about how the company is advancing its programs and why those programs matter to patients.
Inside the Fireside Chat
Artiva’s management team will discuss recent progress and priorities across its cell therapy programs for autoimmune diseases and cancers. Expect an update on strategy, clinical development, and where the company sees the greatest opportunity to help patients. In addition to the public session, the team will hold one-on-one meetings with registered investors, offering a closer look at milestones, plans, and the company’s broader vision.
Artiva’s Focus and Platform
Artiva operates with a practical aim: develop accessible, effective cell therapies that can change how difficult diseases are treated. The company’s lead program, AlloNK®, is an allogeneic NK cell therapy designed to enhance B-cell depletion when used with monoclonal antibodies. AlloNK® is in clinical trials in systemic lupus erythematosus and multiple autoimmune indications. Together, these efforts reflect a clear focus on conditions with high burdens for patients and limited therapeutic options.
Pipeline and Progress
Beyond AlloNK®, Artiva is advancing CAR-NK candidates targeting a range of hematologic and solid tumors. These programs are built to broaden the potential reach of NK cell therapies across cancer types. Founded in 2019 as a spinoff of a respected healthcare company in Korea, Artiva’s work is grounded in exclusive rights to advanced NK cell manufacturing technologies—an important base for moving programs from research into the clinic with intent and consistency.
How to Watch the Conference
The fireside chat will be available via live webcast on the company’s website, giving the community and potential investors a straightforward way to listen in. A replay will be posted shortly after the event for anyone who can’t join live. This open access underscores Artiva’s ongoing commitment to engage transparently with patients, caregivers, and stakeholders.
About Artiva Biotherapeutics
Based in San Diego, California, Artiva Biotherapeutics continues to build and refine its platform to deliver cell therapies for people with pressing medical needs. The company blends advanced research with a patient-centered mindset—aiming to make therapies that are not only innovative, but also practical and impactful in real-world care.
Frequently Asked Questions
What will be covered in Artiva’s fireside chat?
Company leadership plans to discuss recent progress, strategy, and next steps for cell therapies addressing autoimmune diseases and cancers, along with their broader vision for patient impact.
When will the fireside chat take place?
The exact date and time will be shared closer to the event. The session is part of the 2024 Cantor Fitzgerald Global Healthcare Conference.
How can I access the webcast and replay?
You can listen live through the Investors section of Artiva’s website. A recorded replay will be available shortly after the event.
What therapies are in Artiva’s pipeline?
Artiva’s pipeline includes AlloNK®, an allogeneic NK cell therapy designed to enhance B-cell depletion with monoclonal antibodies and in trials for systemic lupus erythematosus and other autoimmune indications, as well as CAR-NK candidates targeting hematologic and solid tumors.
Where is Artiva Biotherapeutics headquartered?
Artiva Biotherapeutics is headquartered in San Diego, California, a major hub for biotechnology research and development.
